Who owns BioMarin Pharmaceutical (BMRN)? Superinvestor holders
3 superinvestors of the 157 tracked here hold BioMarin Pharmaceutical (BMRN) in their latest 13F filing, with $2.2B between them. Andreas Halvorsen gives it the most weight: 1.24% of the reported portfolio. In their latest reported quarter, Andreas Halvorsen and Primecap team added; Dodge & Cox team reduced.
Steve Cohen and Ken Fisher sold out of it in their latest quarter.
Key facts
- Superinvestors holding it
- 3 of 157
- Biggest holder
- Primecap team, $899.3M
- Largest weight
- Andreas Halvorsen, 1.24%of their portfolio
- Combined value
- $2.2B
- Bought last quarter
- 2
- Sold last quarter
- 3
From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.
| # | Investor | Share of their portfolio | Value | Shares | Last quarter | Shares moved | Quarter |
|---|---|---|---|---|---|---|---|
| 1 | Andreas HalvorsenViking Global Investors | 1.24% | $435.8M | 7.62M | ▲ Added 7.9% | +554.38K | Q2 2026 |
| 2 | Primecap teamPrimecap Management | 0.56% | $899.3M | 14.99M | ▲ Added 5.6% | +798.9K | Q3 2026 |
| 3 | Dodge & Cox teamDodge & Cox | 0.47% | $877.5M | 14.63M | ▼ Reduced 1.5% | −219.71K | Q3 2026 |
Sold out last quarter
- Steve Cohenwas $67.7M · Q2 2026
- Ken Fisherwas $2M · Q3 2026
Quarter by quarter
| Quarter | Filings in | Holders | Combined shares | Combined value | Bought | Sold |
|---|---|---|---|---|---|---|
| Q3 2026 | 92 | 2 | 29.61M | $1.8B | 1 | 2 |
| Q2 2026 | 157 | 3 | 36.65M | $2.1B | 2 | 2 |
| Q1 2026 | 157 | 5 | 48.01M | $2.7B | 3 | 4 |
| Q4 2025 | 157 | 7 | 45.38M | $2.7B | 4 | 3 |
| Q3 2025 | 157 | 4 | 44.17M | $2.4B | 1 | 3 |
| Q2 2025 | 157 | 5 | 51.58M | $2.8B | 4 | 2 |
| Q1 2025 | 156 | 5 | 49.95M | $3.5B | 3 | 1 |
| Q4 2024 | 156 | 4 | 46.95M | $3.1B | 2 | 2 |
A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.
Each holder's shares
| Investor | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Primecap team | 14.99M | 14.19M | 14.19M | 14.55M | 15.23M | 15.77M | 17.77M | 18.19M |
| Dodge & Cox team | 14.63M | 14.84M | 14.56M | 14.57M | 14.69M | 15.11M | 14.96M | 14.75M |
| Andreas Halvorsen | · | 7.62M | 7.06M | 6.04M | 8.32M | 12.29M | 10.8M | 10.51M |
| Cliff Asness | · | — | 7.68M | 6.69M | 5.93M | 5.58M | 2.93M | — |
| Ken Griffin | · | — | 4.51M | — | — | — | — | — |
| Israel Englander | · | — | — | 3.04M | — | 2.83M | — | — |
| Louis Bacon | — | — | — | 325K | — | — | — | — |
| Robert Pitts | · | — | — | 168K | — | — | — | — |
| Paul Singer | · | — | — | — | — | — | 3.5M | 3.5M |
A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.
Questions and answers
Which superinvestors own BMRN?
In their latest 13F filings: Andreas Halvorsen (1.24% of the portfolio, $435.8M), Primecap team (0.56% of the portfolio, $899.3M), Dodge & Cox team (0.47% of the portfolio, $877.5M).
Who bought BMRN last quarter?
Andreas Halvorsen (added 7.9%), Primecap team (added 5.6%). “Last quarter” is each investor's latest reported quarter.
Who sold BMRN last quarter?
Reduced: Dodge & Cox team (1.5% fewer shares). Sold out entirely: Steve Cohen (was $67.7M), Ken Fisher (was $2M).
How current is this?
It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.
Learn
Cite this page
Funkfolio, “Who owns BioMarin Pharmaceutical (BMRN)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/BMRN/superinvestors
Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.
Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to BMRN by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.